▶ ORFORGLIPRON · SUBTOPIC · SAFETY PROFILE
ORFORGLIPRON Safety Profile
For Laboratory Research Use Only. This page summarises observed adverse events and regulatory status reported in the peer- reviewed literature. It is not medical advice and does not recommend any human use of ORFORGLIPRON.
OBSERVED ADVERSE EVENTS IN LITERATURE
The following adverse events have been observed in trials or animal studies of ORFORGLIPRON. Severity, frequency, and attribution depend on the source publication.
- GI: nausea, diarrhea, vomiting (titration-dependent)
- Decreased appetite
DRUG INTERACTIONS
The following interactions are reported in or theorised from the published mechanism for ORFORGLIPRON.
- Standard GLP-1 class · oral medication absorption (delayed gastric emptying)
CONTRAINDICATIONS REPORTED IN LITERATURE
Contraindications recorded for ORFORGLIPRON in the published record:
- History of MTC or MEN2 (class precaution)
FDA REGULATORY STATUS
Investigational. Phase 3 ACHIEVE/ATTAIN programs ongoing.
WADA REGULATORY STATUS
Not currently listed on the WADA Prohibited List.
SAFETY Q+A FROM LITERATURE
▶ Is orforglipron FDA-approved?
Not yet as of 2026-05. Phase 3 ACHIEVE-1 (T2D) and ATTAIN-1 (obesity) programs are ongoing.
CITED LITERATURE
The safety statements above are drawn from the following peer-reviewed sources. Refer to the originals for adverse- event tables, attribution, and full context.
- Wharton S, et al.. Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity. N Engl J Med 2023. PMID 37364188. link
- Frias JP, et al.. Efficacy and safety of an orally administered GLP-1 receptor agonist (orforglipron) in adults with type 2 diabetes. N Engl J Med 2023. link
RELATED PAGES
▶ LAST UPDATED · 2026-05-19